Different approaches for patent ductus arteriosus in premature infants using acetaminophen

Aimann Surak; Amish Jain; Abbas Hyderi

doi:10.1007/s12519-022-00526-4

Different approaches for patent ductus arteriosus in premature infants using acetaminophen

World J Pediatr. 2022 Apr;18(4):243-250. doi: 10.1007/s12519-022-00526-4. Epub 2022 Mar 6.

Authors

Aimann Surak¹, Amish Jain², Abbas Hyderi³

Affiliations

¹ Northern Alberta Neonatal Program Royal Alexandra Hospital Site NICU, DTC 5027, Stollery Children Hospital, University of Alberta, 10240 Kingsway NW, Edmonton, AB, T5H 3V9, Canada. aimannsurak@gmail.com.
² Department of Pediatrics, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada.
³ Northern Alberta Neonatal Program Royal Alexandra Hospital Site NICU, DTC 5027, Stollery Children Hospital, University of Alberta, 10240 Kingsway NW, Edmonton, AB, T5H 3V9, Canada.

PMID: 35253098
DOI: 10.1007/s12519-022-00526-4

Abstract

Background: Acetaminophen use for pharmacological treatment of hemodynamically significant patent ductus arteriosus (hsPDA) in preterm infants is becoming more popular with emerging evidence that it is effective as well as safe alternative for other agents used to close hsPDA.

Data sources: We performed a narrative review of literature about pharmacological treatment of PDA using acetaminophen.

Results: Acetaminophen was used as a prophylaxis, symptomatic, targeted, and a rescue approach.

Conclusions: It appears that acetaminophen could be used in different approaches to close the hsPDA. Long-term outcomes of acetaminophen exposure early in life still lack certainty.

Keywords: Acetaminophen; Ligation; Patent ductus arteriosus; Preterm.

Publication types

Review

MeSH terms

Acetaminophen / therapeutic use
Ductus Arteriosus, Patent* / diagnostic imaging
Ductus Arteriosus, Patent* / drug therapy
Ductus Arteriosus, Patent* / prevention & control
Humans
Infant
Infant, Low Birth Weight
Infant, Newborn
Infant, Premature

Substances

Acetaminophen